{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:40:03Z","timestamp":1739324403539,"version":"3.37.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s11936-009-0042-4","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T19:39:31Z","timestamp":1252438771000},"page":"403-409","source":"Crossref","is-referenced-by-count":4,"title":["Pharmaceutical management of decompensated heart failure syndrome in children: Current state of the art and a new approach"],"prefix":"10.1007","volume":"11","author":[{"given":"Avihu Z.","family":"Gazit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phineas P.","family":"Oren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,9]]},"reference":[{"key":"42_CR1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.healun.2004.06.011","volume":"23","author":"M.M. Boucek","year":"2004","unstructured":"Boucek MM, Edwards LB, Keck BM, et al.: Registry for the International Society for Heart and Lung Transplantation: seventh official pediatric report: 2004. J Heart Lung Transplant 2004, 23:933\u2013947.","journal-title":"J Heart Lung Transplant"},{"key":"42_CR2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1056\/NEJM200003093421003","volume":"342","author":"R.E. McCarthy","year":"2000","unstructured":"McCarthy RE, Bohemer JP, Hruban RH, et al.: Long term outcomes of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000, 342:690\u2013695.","journal-title":"N Engl J Med"},{"key":"42_CR3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1067\/mtc.2001.115243","volume":"122","author":"B.W. Duncan","year":"2001","unstructured":"Duncan BW, Bohn EJ, Atz AM, et al.: Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg 2001, 122:440\u2013448.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"42_CR4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0003-4975(01)03027-2","volume":"73","author":"B.W. Duncan","year":"2002","unstructured":"Duncan BW: Mechanical circulatory support for infant and children with cardiac disease. Ann Thorac Surg 2002, 73:1670\u20131677.","journal-title":"Ann Thorac Surg"},{"key":"42_CR5","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.healun.2004.11.092","volume":"24","author":"I.J. Addonizio","year":"2005","unstructured":"Addonizio IJ, Zangwill SD, Rosenthal DN, et al.: Have changes in UNOS status system improved allocation in pediatric heart recipients [abstract]? J Heart Lung Transplant 2005, 24:S64\u2013S65.","journal-title":"J Heart Lung Transplant"},{"key":"42_CR6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1378\/chest.130.4.1198","volume":"130","author":"S. Rich","year":"2006","unstructured":"Rich S: The current treatment of pulmonary hypertension: time to redefine success. Chest 2006, 130:1198\u20131202.","journal-title":"Chest"},{"key":"42_CR7","first-page":"1825","volume-title":"Goodman & Gilman\u2019s the Pharmacological Basis of Therapeutics","author":"J.G. Hardman","year":"2001","unstructured":"Hardman JG, Limbird LE, Gilman AG: Goodman & Gilman\u2019s the Pharmacological Basis of Therapeutics. Columbus, OH: McGraw-Hill; 2001:1825."},{"key":"42_CR8","first-page":"237","volume-title":"Goodman & Gilman\u2019s the Pharmacologic Basis of Therapeutics","author":"T.C. Westfall","year":"2005","unstructured":"Westfall TC, Westfall DP: Adrenergic agonists and antagonists. In Goodman & Gilman\u2019s the Pharmacologic Basis of Therapeutics. Edited by Brunton LL, Lazo JS, Parker KL. New York: McGraw Hill; 2005:237\u2013295."},{"key":"42_CR9","first-page":"200","volume":"301","author":"H. Hashimoto","year":"1989","unstructured":"Hashimoto H, Kunitada S, Tamura K: Functional and metabolic effects of bucladesine (dibutyryl cyclic AMP) in the working rat heart preparation: comparison with dopamine. Arch Int Pharmacodyn Ther 1989, 301:200\u2013214.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"42_CR10","first-page":"151","volume-title":"Pediatric Cardiac Intensive Care","author":"B.S. Marino","year":"1998","unstructured":"Marino BS, Wernovski G: Preoperative care. In Pediatric Cardiac Intensive Care. Edited by Chang AC, Hanley F, Wernovsky G, Wessel DL. Baltimore: Lippincott Williams & Wilkins; 1998:151\u2013162."},{"key":"42_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/00006534-198710000-00024","volume":"80","author":"B.K. Siwy","year":"1987","unstructured":"Siwy BK, Sadove AM: Acute management of dopamine infiltration injury with regitine. Plast Reconstr Surg 1987, 80:610.","journal-title":"Plast Reconstr Surg"},{"key":"42_CR12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-3476(82)80534-9","volume":"100","author":"R.M. Perkin","year":"1982","unstructured":"Perkin RM, Levin DL, Webb R, et al.: Dobutamine: a hemodynamic evaluation in children with shock. J Pediatr 1982, 100:977\u2013983.","journal-title":"J Pediatr"},{"key":"42_CR13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00003246-199305000-00010","volume":"21","author":"R.A. Berg","year":"1993","unstructured":"Berg RA, Donnerstein RL, Padbury JF: Dobutamine in stable, critically ill children: pharmacokinetics and hemodynamic actions. Crit Care Med 1993, 21:678\u2013686.","journal-title":"Crit Care Med"},{"key":"42_CR14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00003246-199205000-00010","volume":"20","author":"D.M. Habib","year":"1992","unstructured":"Habib DM, Padbury JF, Anas NG, et al.: Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit Care Med 1992, 20:601\u2013608.","journal-title":"Crit Care Med"},{"key":"42_CR15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0002-9149(79)90016-X","volume":"45","author":"D.J. Driscoll","year":"1979","unstructured":"Driscoll DJ, Gillette PC, Duff DF, et al.: Hemodynamic effects of dobutamine in children. Am J Cardiol 1979, 45:581\u2013585.","journal-title":"Am J Cardiol"},{"key":"42_CR16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-3476(82)80534-9","volume":"100","author":"R.M. Perkin","year":"1982","unstructured":"Perkin RM, Levin DL, Webb R, et al.: Dobutamine: a hemodynamic evaluation in children with shock. J Pediatr 1982, 100:977\u2013983.","journal-title":"J Pediatr"},{"key":"42_CR17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","volume":"138","author":"C.M. O\u2019Connor","year":"1999","unstructured":"O\u2019Connor CM, Gattis WA, Uretsky BF, et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78\u201386.","journal-title":"Am Heart J"},{"key":"42_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1098-3597(00)90029-2","volume":"3","author":"A.B. Bakel Van","year":"2000","unstructured":"Van Bakel AB, Chidsey G: Management of advanced heart failure. Clin Cornerstone 2000, 3:25\u201335.","journal-title":"Clin Cornerstone"},{"key":"42_CR19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0749-0704(18)30297-5","volume":"7","author":"D.A. Notterman","year":"1991","unstructured":"Notterman DA: Inotropic agents, catecholamines, digoxin, amrinone. Crit Care Clin 1991, 7:583\u2013613.","journal-title":"Crit Care Clin"},{"key":"42_CR20","first-page":"709","volume":"55","author":"R.R. Johnson","year":"1976","unstructured":"Johnson RR, Eger EI 2nd, William C: A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. Anesth Analg 1976, 55:709\u2013712.","journal-title":"Anesth Analg"},{"key":"42_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/cc3901","volume":"9","author":"B. Levy","year":"2005","unstructured":"Levy B: Bench-to-bedside review: is there a place for epinephrine in septic shock? Crit Care 2005, 9:561\u2013565.","journal-title":"Crit Care"},{"key":"42_CR22","first-page":"864","volume":"8","author":"C.Q. Earl","year":"1986","unstructured":"Earl CQ, Linden J: Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. J Cardiovasc Pharmacol 1986, 8:864\u2013872.","journal-title":"J Cardiovasc Pharmacol"},{"key":"42_CR23","first-page":"III145","volume":"73","author":"J. Edelson","year":"1986","unstructured":"Edelson J, Stroshane R, Benziger DP, et al.: Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 1986, 73:III145\u2013III152.","journal-title":"Circulation"},{"key":"42_CR24","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"M.S. Cuffe","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams KF Jr, et al.: Short term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541\u20131547.","journal-title":"JAMA"},{"key":"42_CR25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"G.M. Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, et al.: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003, 41:997\u20131003.","journal-title":"J Am Coll Cardiol"},{"key":"42_CR26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1054\/jcaf.2003.24","volume":"9","author":"R.E. Hershberger","year":"2003","unstructured":"Hershberger RE, Nauman D, Walker TL, et al.: Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Cardiac Fail 2003, 9:180\u2013187.","journal-title":"J Cardiac Fail"},{"key":"42_CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cardfail.2005.11.001","volume":"12","author":"J.F. Price","year":"2006","unstructured":"Price JF, Towbin JA, Dreyer WJ, et al.: Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure. J Card Fail 2006, 12:139\u2013143.","journal-title":"J Card Fail"},{"key":"42_CR28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.healun.2007.02.004","volume":"26","author":"A.M. Berg","year":"2007","unstructured":"Berg AM, Snell L, Mahle WT: Home inotropic therapy in children. J Heart Lung Transplant 2007, 26:453\u2013457.","journal-title":"J Heart Lung Transplant"},{"key":"42_CR29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)30018-2","volume":"191","author":"R.P. Smith","year":"1974","unstructured":"Smith RP, Kruszyna H: Nitroprusside produces cyanide poisoning via a reaction with hemoglobin. J Pharmacol Exp Ther 1974, 191:557\u2013563.","journal-title":"J Pharmacol Exp Ther"},{"key":"42_CR30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJM197409192911201","volume":"291","author":"N.H. Guiha","year":"1974","unstructured":"Guiha NH, Cohn JN, Mikulic E, et al.: Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974, 291:587\u2013592.","journal-title":"N Engl J Med"},{"key":"42_CR31","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa022021","volume":"348","author":"U.N. Khot","year":"2003","unstructured":"Khot UN, Novaro GM, Popovic ZB, et al.: Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003, 348:1756\u20131763.","journal-title":"N Engl J Med"},{"key":"42_CR32","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0735-1097(02)01814-4","volume":"39","author":"W. Johnson","year":"2002","unstructured":"Johnson W, Omland T, Hall C, et al.: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002, 39:1623\u20131629.","journal-title":"J Am Coll Cardiol"},{"key":"42_CR33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1161\/01.CIR.0000141829.04031.25","volume":"110","author":"D.J. Wang","year":"2004","unstructured":"Wang DJ, Dowling TC, Meadows D, et al.: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004, 110:1620\u20131625.","journal-title":"Circulation"},{"key":"42_CR34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.PCC.0000164634.58297.9A","volume":"6","author":"W.T. Mahle","year":"2005","unstructured":"Mahle WT, Cuadrado AR, Kirshbom PM, et al.: Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 2005, 6:543\u2013546.","journal-title":"Pediatr Crit Care Med"},{"key":"42_CR35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00246-005-1294-8","volume":"27","author":"J.L. Jefferies","year":"2006","unstructured":"Jefferies JL, Denfield SW, Price JF, et al.: A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol 2006, 27:402\u2013407.","journal-title":"Pediatr Cardiol"},{"key":"42_CR36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/0885066608320840","volume":"23","author":"A. Ryan","year":"2008","unstructured":"Ryan A, Rosen DA, Tobias JD: Preliminary experience with nesiritide in pediatric patients less than 12 months of age. J Intensive Care Med 2008, 23:321\u2013328.","journal-title":"J Intensive Care Med"},{"key":"42_CR37","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0735-1097(01)01818-6","volume":"39","author":"M.A. Silver","year":"2002","unstructured":"Silver MA, Horton DP, Ghali JK, Elkayam U: Effect of nesiritide versus dobutamine on short term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002, 39:798\u2013803.","journal-title":"J Am Coll Cardiol"},{"key":"42_CR38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","volume":"111","author":"J.D. Sackner-Bernstein","year":"2005","unstructured":"Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487\u20131491.","journal-title":"Circulation"},{"key":"42_CR39","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","volume":"293","author":"J.D. Sackner-Bernstein","year":"2005","unstructured":"Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900\u20131905.","journal-title":"JAMA"},{"key":"42_CR40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJM199307153290310","volume":"329","author":"M. Packer","year":"1993","unstructured":"Packer M: The search for the ideal positive inotropic agent. N Engl J Med 1993, 329:201\u2013202.","journal-title":"N Engl J Med"},{"key":"42_CR41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"G.M. Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, et al.: OPTIMECHF Investigators: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003, 41:997\u20131003.","journal-title":"J Am Coll Cardiol"},{"key":"42_CR42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1388-9842(02)00041-7","volume":"4","author":"S. Thackray","year":"2002","unstructured":"Thackray S, Easthaugh J, Freemantle N, Cleland JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002, 4:515\u2013529.","journal-title":"Eur J Heart Fail"},{"key":"42_CR43","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1071-9164(03)00532-3","volume":"9","author":"M. Packer","year":"2003","unstructured":"Packer M, Colucci WS, Fisher L, et al.: Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study [abstract]. J Card Fail 2003, 9:S61.","journal-title":"J Card Fail"},{"key":"42_CR44","doi-asserted-by":"crossref","unstructured":"Mebazaa A, Cohen-Solal A, Kleber F, et al.: Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure [abstract 231]. Presented at the Eighth Annual Scientific Meeting of the Heart Failure Society of America. Toronto, Canada; September 12\u201315, 2004.","DOI":"10.1016\/j.cardfail.2004.06.230"},{"key":"42_CR45","doi-asserted-by":"crossref","first-page":"68G","DOI":"10.1016\/j.amjcard.2005.07.023","volume":"96","author":"M. Gheorghiade","year":"2005","unstructured":"Gheorghiade M, Teerlink JR, Mebazaa A: Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005, 96:68G\u201373G.","journal-title":"Am J Cardiol"},{"key":"42_CR46","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"V.S. Moiseyev","year":"2002","unstructured":"Moiseyev VS, Poder P, Andrejevs N, et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23:1422\u20131432.","journal-title":"Eur Heart J"},{"key":"42_CR47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F. Follath","year":"2002","unstructured":"Follath F, Cleland JG, Just H, et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196\u2013202.","journal-title":"Lancet"},{"key":"42_CR48","doi-asserted-by":"crossref","unstructured":"Zairis MN, Apostolatos C, Anastassiadis F, et al.: Comparison of the effect of levosimendan, or dobutamine or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or None in Low Output Heart Failure (CASINO) Study [abstract 273]. Presented at the European Society of Cardiology Heart Failure Update. Wroclaw, Poland; June 12\u201315, 2004.","DOI":"10.1016\/S1567-4215(04)90194-4"},{"key":"42_CR49","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0022-3565(24)34972-9","volume":"290","author":"M. Clozel","year":"1999","unstructured":"Clozel M, Ramuz H, Clozel JP, et al.: Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999, 290:840\u2013846.","journal-title":"J Pharmacol Exp Ther"},{"key":"42_CR50","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M. Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690\u20132696.","journal-title":"Circulation"},{"key":"42_CR51","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M. Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963\u20131971.","journal-title":"JAMA"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-009-0042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-009-0042-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-009-0042-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:17:21Z","timestamp":1739323041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-009-0042-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1007\/s11936-009-0042-4","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"type":"print","value":"1092-8464"},{"type":"electronic","value":"1534-3189"}],"subject":[],"published":{"date-parts":[[2009,9,9]]}}}